LublinFDReingoldSC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology1996; 46: 907–911.
3.
PittockSJMcClellandRLMayrWT. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol2004; 56: 303–306.
4.
RamsaransingGSDe KeyserJ. Benign course in multiple sclerosis: a review. Acta Neurol Scand2006; 113: 359–369.
5.
SayaoALDevonshireVTremlettH. Longitudinal follow-up of "benign" multiple sclerosis at 20 years. Neurology2007; 68: 496–500.
6.
De StefanoNBattagliniMStromilloML. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain2006; 129: 2008–2016.
7.
AmatoMPZipoliVGorettiB. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol2006; 253: 1054–1059.
8.
RovarisMBarkhofFCalabreseM. MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. Neurology2009; 72: 1693–1701.
9.
AmatoMPPortaccioEStromilloML. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology2008; 71: 632–638.
10.
RovarisMRiccitelliGJudicaE. Cognitive impairment and structural brain damage in benign multiple sclerosis. Neurology2008; 71: 1521–1526.
11.
PortaccioEStromilloMLGorettiB. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology2009; 73: 498–503.
